EVALI: A Diagnosis of Exclusion Amidst the COVID-19 Pandemic
EVALI and COVID-19 manifest with similar clinical and imaging findings
March 02, 2022
Patients with e-cigarette or vaping-induced lung injury (EVALI) typically have a nonspecific clinical presentation characterized by a constellation of respiratory, gastrointestinal and constitutional symptoms. However, before an EVALI diagnosis can be made, the patient must have a history of recent vaping within 90 days, other etiologies must be excluded, and opacities must be present on chest imaging.
Imaging is important in patients with acute lung injury to ensure early detection. EVALI’s symptoms can be very similar to many other respiratory diseases — including COVID-19.
See the infographic below for information about how EVALI and COVID-19 are similar and different.
Read more about EVALI in previous RSNA News articles:
Editor's Picks
From the Reading Room to Leadership: Lessons from the Top
High-quality Symptom Information Dramatically Improves the Reports of Lumbar Spine MRI
Ultra-Low Dose CT Aids Pneumonia Diagnosis in Immunocompromised Patients
Research Into MRI Contrast Agent Wins Neuroradiology Research Award